Adderall pills in a bottle|Tony Webster|CC BY 2.0
Mental telehealth startup Cerebral—valued at $4.8 billion—announced on Wednesday that they would stop prescribing Adderall for ADHD patients.
The decision is followed by Truepill, Cerebral’s preferred pharmacy, announcing their halt of prescriptions for Adderall and other controlled substances last week.
Why?
The move comes amid concerns that the startup overprescribes medicines. Last week the company was sued by its former VP of product and engineering for overprescribing ADHD medicines.
Clinicians of the telehealth company will continue to treat its existing ADHD patients and prescribe them stimulants.
